Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for prevention of chemotherapy-induced nausea and vomiting in children with cancer
IRCT20200204046377N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Aprepitant + ondansetron with Placebo + ondansetron (2 arms). Primary endpoint: Nausea and vomiting. Started Feb 2020; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on IRCT20200204046377N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200204046377N1.